MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for MeiraGTx Holdings PLC despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.50 per share, reflecting a year-over-year change of +7.4%, while revenues are projected to be $4.08 million, down 62.6% from the previous year [3]. - The consensus EPS estimate has been revised 6.14% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP of +2.00% indicates a likelihood of beating the consensus EPS estimate, although the stock currently holds a Zacks Rank of 3 [12]. - Historical performance shows that MeiraGTx has beaten consensus EPS estimates only once in the last four quarters, with a recent surprise of +7.69% when it reported a loss of -$0.48 instead of the expected -$0.52 [13][14]. Industry Context - X4 Pharmaceuticals, another player in the biomedical and genetics sector, is expected to report a loss of $0.79 per share, with revenues projected at $1.9 million, reflecting a year-over-year increase of 239.3% [18]. - Despite a recent upward revision of 14.6% in EPS estimates for X4 Pharmaceuticals, it has a negative Earnings ESP of -80.32%, complicating predictions for beating consensus estimates [19][20].